IASO: Neonatal BabyGen – Neonatal Genomic Screening
IASO, the largest Maternity & Gynecology Clinic in Europe, in collaboration with Neoscreen, introduces the Neonatal BabyGen genomic screening, an innovative examination that paves the way for the future of preventive medicine.
Neonatal BabyGen is a screening that enables the early detection of serious genetic, metabolic, and rare disorders through the analysis of a newborn’s DNA, from the very first days of their life. The screening focuses on a targeted analysis of 500 – 600 high-significance genes that are associated with hereditary conditions, metabolic disorders, rare but serious syndromes and conditions that can be prevented or treated. In this way, parents and treating physicians gain valuable insight that allows for early prevention, monitoring and, where necessary, therapeutic intervention, even before symptoms appear.
The process is simple, painless, and completely safe: only a few drops of blood are needed, which are analyzed using Next Generation Sequencing (NGS) technology. The results are delivered to parents within 15–20 business days and are accompanied by clinical genetic counseling.
Neoscreen is a specialized laboratory in Greece, having the technological capability for comprehensive genomic screening, with 20 years of experience in neonatal clinical screening and over 10 years of expertise in genome analysis.
With Neonatal BabyGen, IASO and Neoscreen offer parents the opportunity to give their children an invaluable gift: knowledge about the future of their health.
